Effect of protein kinase inhibitors on the stretch-elicited c-Fos and c-Jun up-regulation in human PDL osteoblast-like cells.
Osteoblastic cells transduce signals of mechanical loading that plays a key role in maintaining bone formation. In an attempt to elucidate the biochemical events associated with the conversion of mechanical stress to biological outcome, we examined cultured human periodontal ligament (hPDL) osteoblastic cells exposed to continuous stretch, in terms of cellular parameters correlating known signaling cascades to the initial phase of osteoblast-specific transcriptional control. Time-course experiments revealed that mechanical stretch-loaded hPDL cells exhibit a very rapid and relatively sustained increase in the abundance of the immediate-early gene products, c-Fos and c-Jun, components of the activator protein-1 (AP-1) transcription factor. Moreover, this increase in protein levels was accompanied by hyperphosphorylation and thereby potentiation of c-Jun, the principal modulator of AP-1 activity. Importantly, these inductive effects were partly or completely abolished by pre-incubating the cells with SB 203580, PD 098059, and the novel compound Y-27632, inhibitors of p38 mitogen-activated protein kinase (MAPK), MAPK kinase (MEK), and Rho-associated protein kinase (RhoK), respectively. These results consolidate AP-1 as the pivotal downstream effector in the early response of hPDL cells to continuous mechanical stretching, via the coordinate stimulation of de novo synthesis and post-translational regulation of AP-1 proteins. This "integrating" function of AP-1 is mediated through a mechanotransduction circuit that incorporates elements of well-defined upstream signaling protein kinase systems.
Kletsas
Dimitris
D
Institute of Biology, N.C.S.R. Demokritos, Athens, Greece.
Basdra
Efthimia K
EK
Papavassiliou
Athanasios G
AG
D000577:Amides / Q000494:pharmacology; D002352:Carrier Proteins / Q000494:pharmacology*; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D047908:Intracellular Signaling Peptides and Proteins; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D010006:Osteoblasts / Q000378:metabolism*; D010513:Periodontal Ligament / Q000166:cytology / Q000378:metabolism*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology; D013314:Stress, Mechanical; D015854:Up-Regulation / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases; D054460:rho-Associated Kinases
D000577:Amides; D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D005419:Flavonoids; D007093:Imidazoles; D047908:Intracellular Signaling Peptides and Proteins; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D011725:Pyridines; C015482:protein kinase modulator; C108830:Y 27632; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one